The Appearance of Xylazine in the United States as a Fentanyl Adulterant

Caitlin E. Leconte, BA; Roopa Sethi, MD

Prim Care Companion CNS Disord 2023;25(6):22nr03473

ABSTRACT

Importance: Use of xylazine in the United States as an adulterant for drugs of abuse has increased in recent years, thus it is important for health care providers to understand the basic pharmacology and toxidrome of the drug, as well as management options for patients who have overdosed.

Observations: Data obtained from studies between 2006 and 2022 indicate a rapidly increasing incidence of xylazine overdose in the United States, with overdose cases now being seen in 25 states. Hallmark symptoms of xylazine overdose include respiratory depression, bradycardia, hyperglycemia, central nervous system depression, and initial hypertension turning to unstable blood pressure. Xylazine overdose is not reversible with naloxone and requires supportive measures.

Conclusions and Relevance: It is important for health care providers to be aware of presenting symptoms in xylazine overdose so that proper care can be provided. Facilities may consider adding xylazine to their routine toxicology report to aid in patient management and better assess the incidence of xylazine use as an adulterant in a given geographic area.

Prim Care Companion CNS Disord 2023;25(6):22nr03473

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Download Free PDF

References (14)

Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. Subst Abuse Treat Prev Policy. 2011;6(1):7. PubMed CrossRef
Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, et al. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8. PubMed CrossRef
Wong SC, Curtis JA, Wingert WE. Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia Medical Examiner’s Office. J Forensic Sci. 2008;53(2):495–498. PubMed CrossRef
Hoffmann U, Meister CM, Golle K, et al. Severe intoxication with the veterinary tranquilizer xylazine in humans. J Anal Toxicol. 2001;25(4):245–249. PubMed CrossRef
Nunez J, DeJoseph ME, Gill JR. Xylazine, a veterinary tranquilizer, detected in 42 accidental fentanyl intoxication deaths. Am J Forensic Med Pathol. 2021;42(1):9–11. PubMed CrossRef
Johnson J, Pizzicato L, Johnson C, et al. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019. Inj Prev. 2021;27(4):395–398. PubMed CrossRef
Kariisa M, Patel P, Smith H, et al. Notes from the field: xylazine detection and involvement in drug overdose deaths– United States, 2019. MMWR Morb Mortal Wkly Rep. 2021;70(37):1300–1302. PubMed CrossRef
Korn WR, Stone MD, Haviland KL, et al. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta. 2021;521:151–154. PubMed CrossRef
Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. PubMed CrossRef
Rodríguez N, Vargas Vidot J, Panelli J, et al. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend. 2008;96(3):290–293. PubMed CrossRef
Meyer GM, Maurer HH. Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MSn, and LC-HR-MSn. Anal Bioanal Chem. 2013;405(30):9779–9789. PubMed CrossRef
Whitlock J. The use of xylazine hydrochloride in free roaming and wild mammals. Iowa State Univ Vet. 1974;36(3):109–110.
Garcia-Villar R, Toutain PL, Alvinerie M, et al. The pharmacokinetics of xylazine hydrochloride: an interspecific study. J Vet Pharmacol Ther. 1981;4(2):87–92. PubMed CrossRef
Lavoie DS-G, Pailleux F, Vachon P, et al. Characterization of xylazine metabolism in rat liver microsomes using liquid chromatography-hybrid triple quadrupole-linear ion trap-mass spectrometry. Biomed Chromatogr. 2013;27(7):882–888. PubMed CrossRef